[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1027820A1 - Molecules that home to a selected organ or tissue in vivo - Google Patents

Molecules that home to a selected organ or tissue in vivo

Info

Publication number
HK1027820A1
HK1027820A1 HK00106023A HK00106023A HK1027820A1 HK 1027820 A1 HK1027820 A1 HK 1027820A1 HK 00106023 A HK00106023 A HK 00106023A HK 00106023 A HK00106023 A HK 00106023A HK 1027820 A1 HK1027820 A1 HK 1027820A1
Authority
HK
Hong Kong
Prior art keywords
peptide
phage
organ
artificial sequence
molecule
Prior art date
Application number
HK00106023A
Other languages
German (de)
English (en)
Chinese (zh)
Other versions
HK1027820B (en
Inventor
Erkki I. Ruoslahti
Renata Pasqualini
Original Assignee
La Jolla Cancer Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/526,710 external-priority patent/US5622699A/en
Application filed by La Jolla Cancer Research Foundation filed Critical La Jolla Cancer Research Foundation
Publication of HK1027820A1 publication Critical patent/HK1027820A1/en
Publication of HK1027820B publication Critical patent/HK1027820B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Claims (9)

  1. Molécule d'adressage sélectif vers une tumeur du sein, qui est un peptide ayant une séquence d'acides aminés choisie dans le groupe constitué de CGRECPRLCQSSC (SEQIDNO: 48), CGEACGGQCALPC (SEQIDNO: 49) et CNGRCVSGCAGRC (SEQ ID NO : 50).
  2. Procédé in vitro pour diriger un fragment vers une tumeur du sein; comprenant les étapes consistant à :
    a. lier le fragment à une molécule selon la revendication 1 pour former un complexe comprenant ledit fragment et ladite molécule ; et
    b. mettre en contact ledit complexe avec la tumeur du sein, ladite molécule selon la revendication 1 se liant sélectivement à la tumeur du sein, dirigeant ainsi ledit fragment vers ladite tumeur du sein.
  3. Procédé selon la revendication 2, dans lequel ledit fragment comprend un marqueur détectable.
  4. Procédé selon la revendication 2 ou 3, dans lequel ledit fragment comprend un agent cytotoxique.
  5. Procédé selon les revendications 2 à 4, dans lequel ledit fragment est un liposome, une microcapsule ou une micropompe.
  6. Utilisation d'une molécule selon la revendication 1 pour préparer une composition pharmaceutique pour diriger un fragment vers une tumeur du sein.
  7. Utilisation selon la revendication 6, dans laquelle ledit fragment comprend un marqueur détectable.
  8. Utilisation selon les revendications 6 ou 7, dans laquelle ledit fragment comprend un agent cytotoxique.
  9. Utilisation selon les revendications 6 à 8, dans laquelle ledit fragment est un liposome, une microcapsule ou une micropompe.
HK00106023.8A 1995-09-11 2000-09-22 Molecules that home to a selected organ or tissue in vivo HK1027820B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US52670895A 1995-09-11 1995-09-11
US08/526,710 US5622699A (en) 1995-09-11 1995-09-11 Method of identifying molecules that home to a selected organ in vivo
US526708 1995-09-11
US526710 1995-09-11

Publications (2)

Publication Number Publication Date
HK1027820A1 true HK1027820A1 (en) 2001-01-23
HK1027820B HK1027820B (en) 2008-07-18

Family

ID=

Also Published As

Publication number Publication date
ES2299232T3 (es) 2008-05-16
CA2204535C (fr) 2002-11-12
JP3900305B2 (ja) 2007-04-04
EP0987275B1 (fr) 2008-01-02
ATE382630T1 (de) 2008-01-15
JP2007204483A (ja) 2007-08-16
JP2003155296A (ja) 2003-05-27
DE69609585D1 (de) 2000-09-07
CA2204535A1 (fr) 1997-03-20
EP0987275A2 (fr) 2000-03-22
AU6973996A (en) 1997-04-01
DE69637395D1 (de) 2008-02-14
WO1997010507A1 (fr) 1997-03-20
DE69609585T2 (de) 2001-04-05
JPH10502674A (ja) 1998-03-10
DE773441T1 (de) 1999-03-04
ATE195181T1 (de) 2000-08-15
EP0987275A3 (fr) 2006-06-21
AU693723B2 (en) 1998-07-02
DE69637395T2 (de) 2008-12-18
EP0773441A1 (fr) 1997-05-14
EP0773441B1 (fr) 2000-08-02
EP0876611A1 (fr) 1998-11-11

Similar Documents

Publication Publication Date Title
EP0987275B1 (fr) Molécules qui s'adressent in vivo vers un organe ou tissu prélevé
US7018615B2 (en) Method of identifying molecules that home to a selected organ in vivo
US5622699A (en) Method of identifying molecules that home to a selected organ in vivo
US6576239B1 (en) Angiogenic homing molecules and conjugates derived therefrom
EP0927045B1 (fr) Molecules se logeant dans une tumeur, conjugues tires de ces molecules et leurs procedes d'utilisation
US6933281B2 (en) Molecules that home to various selected organs or tissues
EP1015884B1 (fr) Procedes relatifs a l'identification de molecules capables de rallier des systemes vasculaires angiogeniques dans les tumeurs
US20040096441A9 (en) NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
US6743892B1 (en) Molecules that home to a selected organ in vivo
AU728668B2 (en) Molecules that home to a selected organ or tissue in vivo and methods of identifying same
HK1027820B (en) Molecules that home to a selected organ or tissue in vivo
HK1029173B (en) Methods of identifying molecules that home to angiogenic vasculature in tumors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110910